Please use this identifier to cite or link to this item:
https://hdl.handle.net/10356/169442
Title: | Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer | Authors: | Neo, Shi Yong Xu, Shengli Chong, Joni Lam, Kong-Peng Wu, Jing |
Keywords: | Science::Biological sciences | Issue Date: | 2023 | Source: | Neo, S. Y., Xu, S., Chong, J., Lam, K. & Wu, J. (2023). Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer. Journal for ImmunoTherapy of Cancer, 11(4), e006434-. https://dx.doi.org/10.1136/jitc-2022-006434 | Project: | NRF-CRP26-2021RS-0001 NMRC/OFLCG/003/2018 |
Journal: | Journal for ImmunoTherapy of Cancer | Abstract: | Cell therapy encompasses an expanding spectrum of cell-based regimes for the treatment of human ailments, such as the use of immune cells, in particular T cells, for combating tumors and the modulation of inflammatory immune responses. In this review, we focus on cell therapy in the immuno-oncology space, which is largely driven by interests and demands from the clinics for better solutions to target various hard-to-treat cancers. We discuss recent advances in various types of cell therapies, including T cell receptor-T cells, chimeric antigen receptor (CAR)-T cells, tumor-infiltrating lymphocytes and natural killer cells. Particularly, the present review focuses on the strategies to improve therapeutic responses by either enhancing tumor recognition or the resilience of infused immune cells within tumor microenvironment. Finally, we discuss the potential of other innate or innate-like immune cell types currently being explored as promising CAR-cell alternatives that seek to address the limitations of conventional adoptive cell therapies. | URI: | https://hdl.handle.net/10356/169442 | ISSN: | 2051-1426 | DOI: | 10.1136/jitc-2022-006434 | Schools: | School of Biological Sciences | Organisations: | Singapore Immunology Network, A*STAR National University of Singapore |
Rights: | © 2023 Author(s) (or their employer(s)). Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/. | Fulltext Permission: | open | Fulltext Availability: | With Fulltext |
Appears in Collections: | SBS Journal Articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
e006434.full.pdf | 777.34 kB | Adobe PDF | ![]() View/Open |
SCOPUSTM
Citations
50
9
Updated on May 4, 2025
Page view(s)
170
Updated on May 7, 2025
Download(s) 50
72
Updated on May 7, 2025
Google ScholarTM
Check
Altmetric
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.